ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 484

Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept

Jipan Xie1, Arijit Ganguli2, Hongbo Yang1, Kejal Parikh1, Eric Q. Wu1 and Mary Cifaldi3, 1Analysis Group Inc., Boston, MA, 2AbbVie, North Chicago, IL, 3Abbott Laboratories, Abbott Park, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA).  The study is aimed to compare the rate of experiencing RA-related urgent care and surgery, and the risk of developing new comorbidities between ADA- and ETN-treated patients with RA.

Methods: Adult RA (ICD-9-CM: 714) patients who initiated ADA or ETN were identified from the Thomson MarketScan database (2005-2009).  The date of the first prescription of ADA or ETN was defined as the index date.  Patients were required to have continuous eligibility for at least 6 months prior to (baseline period) and 12 months after (study period) the index date.  In addition, patients were required to be free of other medical conditions (e.g., Crohn’s disease and psoriasis), for which ADA or ETN is indicated, during the baseline period.  Baseline characteristics (demographics, comorbidities, prior treatments for RA and health care resource use) were compared between the ADA and ETN cohorts using Chi-square tests for categorical variables or Wilcoxon rank-sum tests for continuous variables.  The rate of experiencing RA-related urgent care (i.e., inpatient or emergency room visits associated with RA diagnoses), RA-related surgery, and the risk of developing new comorbidities (including gastrointestinal disease, cardiovascular disease, diabetes, hypertension, osteoporosis) during the study period were compared between the two cohorts using Cox proportional hazards models, adjusting for the above baseline characteristics.

Results: A total of 3,109 ADA-treated RA patients and 3,972 ETN-treated RA patients met the study inclusion and exclusion criteria.  Compared to ETN-treated patients, ADA-treated patients were older (50.2 vs. 49.4, p=0.006), and had a higher baseline use of methotrexate (62.9% vs. 58.7%, p<0.001).  After adjusting for baseline characteristics, ADA was associated with a significant lower rate of experiencing RA-related urgent care (hazard ratio [HR]=0.82, 95% confidence interval [CI]=0.67-0.99) and RA-related surgery (HR=0.65; 95% CI=0.47-0.91).  ADA was also associated with a lower risk of developing new gastrointestinal disease compared to ETN (HR =0.85; 95% CI: 0.76-0.95).  The risks of developing other comorbidities including cardiovascular diseases, diabetes, hypertension, and osteoporosis were not significantly different between the two cohorts. 

Conclusion: Compared to those treated with ETN, patients with RA treated with ADA, were less likely to experience an RA-related urgent care or RA-related surgery, and to develop new gastrointestinal disease.


Disclosure:

J. Xie,

Analysis Group,

3;

A. Ganguli,

Abbott Laboratories,

3,

Abbott Laboratories,

1;

H. Yang,

Analysis Group,

3;

K. Parikh,

Analysis Group,

3;

E. Q. Wu,

Analysis Group,

3;

M. Cifaldi,

Abbott Laboratories,

1,

Abbott Laboratories,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-rheumatoid-arthritis-related-health-care-resource-use-and-comorbidities-among-patients-with-rheumatoid-arthritis-treated-with-adalimumab-vs-etanercept/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology